FDA-approved drug library screen identifies antidepressants, antimicrobials, anti-COPD, and anti-CVD agents as blockers of NLRP3 inflammasome and sepsis in a sex-dependent manner - PubMed
6 hours ago
- #NLRP3 inflammasome
- #sepsis
- #drug repurposing
- FDA-approved drug library screen identifies various drugs as NLRP3 inflammasome blockers.
- Identified drugs include antidepressants, antimicrobials, anti-COPD, and anti-CVD agents.
- NLRP3 inflammasome dysregulation is linked to metabolic, neurodegenerative, and respiratory diseases.
- Therapeutic challenge: selective NLRP3 blockade without broad innate immunity suppression.
- Drugs validated in biochemical assays and murine studies showed reduced inflammation and improved survival.
- Sex-specific effects observed in LPS-induced mortality mouse models.
- Further studies needed for repurposing and therapeutic relevance in human cells and disease models.